Table 1. In Vitro Susceptibilities to Antibiotics Used in the Treatment of Edwardsiella tarda^a  

Antibiotic

n

Range^b

MIC₅₀

MIC₉₀

Break-point^c

Aminoglycosides

Amikacin

150

0.5-8

2-4

2-4

≤16

^d

Gentamicin

189

0.13-4

0.625-1

0.625-2

≤4

^d

Tobramycin

150

0.13-4

0.5-1

0.5-2

≤4

^d

Penicillins

Benzylpenicillin

42

0.5-32

1

2

≤0.1

Amoxicillin

64

0.13-64

0.5

1

≤8

Ampicillin

147

0.12-≥16

0.1-1

0.1-4

≤8

Amoxycillin-clavulanate

65

0.06-4

0.5

0.5-1

≤8

^d

Ampicillin-sulbactam

64

0.06-2

0.25

0.25-1

≤8

^d

Piperacillin

74

0.12-4

0.1-0.25

0.1-0.5

≤16

^d

Piperacillin-tazobactam

64

0.12-0.5

0.13-0.25

0.13-0.25

≤16

^d

Ticarcillin

64

0.13-32

0.13-8

0.25-8

v16

Ticarcillin-clavulanate

22

0.5-4

2

4

≤16

^d 

Cephalosporins

Cefaclor

42

0.13-8

0.5

8

≤8

^d

Cephalothin

108

1-≥64

2-8

2-≥16

≤8

Cefamandole

108

≤0.06-8

≤0.06-1

≤0.06-1

≤8

^d

Cefuroxime

42

≤0.03-0.5

0.13

0.25

≤4

^d

Cefotaxime

189

≤0.03-2

≤0.01-2

0.01-2

≤8

^d

Ceftriaxone

64

≤0.03-0.5

0.03-0.06

0.03-0.06

v8

^d

Cefipime

42

NS

≤0.03

≤0.03

≤8

^d

Carbapenems

Imipenem

74

0.12-0.5

≤0.06-0.25

0.13-0.25

≤4

^d

Meropenem

42

≤0.03

≤0.03

≤0.03

≤4

 ^d

Monobactams

Aztreonam

74

≤0.06-0.13

£0.012-0.06

0.012-0.06

≤8

^d

Quinolones

Ciprofloxacin

103

≤0.03-0.063

0.0001-

≤0.063

0.0001-

≤0.063

≤1

^d

Norfloxacin

81

≤0.063-0.012

0.01-≤0.063

0.01-≤0.063

≤4

^d

Nalidixic acid

29

1-4

2

2

Anti-folates

Trimethoprim

71

≤0.03-1

≤0.03-0.25

0.13-0.25

≤2

^d

Trimethoprim-sulfamethoxazole ^e

71

≤0.063-2

≤0.063-0.13

0.13-1

≤2

^d

Tetracyclines

Tetracycline

157

0.25-≥128

0.5-1

1-≥16

≤4

Doxycycline

52

0.25-≥128

1

1

≤4

Other Antibiotics

Chloramphenicol

128

0.5-≥32

0.5-1

0.5-≥32

≤8

Nitrofurantoin

42

4-8

4

8

≤32

^d

Fosfomycin

42

0.5-32

1

8

≤64

^d